The DIVERSE Trials Act (H.R. 5030/S. 2706) could increase racial, socioeconomic and geographic diversity in clinical trials and make it easier for all cancer patients to participate.
Comments to CMS Regarding National Coverage Decision for Next-Generation Sequencing (NGS) Panels
ACS CAN responded to the reopening of the Centers for Medicare and Medicaid Services (CMS) coverage decision for NGS testing panels. ACS CAN comments stressed that the existing coverage framework improperly freezes coverage based on current science rather than allowing a framework that could evolve with new, validated use cases for NGS technology.